Copertina

Long‐Term Effectiveness of Dupilumab in Moderate‐to‐Severe Atopic Dermatitis Across Different Body Regions in Extended Dosing‐Interval Regimens: A Real‐World Chinese Study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yunmin Zou, Yating Guo, Lu Li, Chun Gu, Haixi Yu, Lingyun Hua, Danning Zhu, Rushan Xia
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Experimental Dermatology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Dupilumab in Combination With JAK Inhibitor for Refractory Moderate‐to‐Severe Atopic Dermatitis
di: Xiaoting Song, et al.
Pubblicazione: (2024)

An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate‐to‐Severe Atopic Dermatitis
di: Sisi Deng, et al.
Pubblicazione: (2024)

Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis
di: Amaia Barrutia‐Etxebarria, et al.
Pubblicazione: (2025)

Long‐Term Safety and Efficacy of Dupilumab in Pediatric Atopic Dermatitis Patients
di: Hilla Bauch-Eigner, et al.
Pubblicazione: (2025)

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib
di: Grigorios Theodosiou, et al.
Pubblicazione: (2026)

A Pediatric Case of Severe Atopic Dermatitis on Dupilumab Treatment and Pulmonary Tuberculosis
di: Maria Efenesia Baffa, et al.
Pubblicazione: (2025)

The Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged Under 12‐Years
di: Laura Wheller, et al.
Pubblicazione: (2026)

Real‐Life Effectiveness of Abrocitinib and Predictors of Response in Adults With Moderate‐To‐Severe Atopic Dermatitis
di: Eugenia Veronica Di Brizzi, et al.
Pubblicazione: (2026)

Real‐World Experience With Dupilumab Treatment in Children and Adolescents With Moderate‐to‐Severe Atopic Dermatitis in a Clinically Diverse Population: A 52‐Week Multicenter Study
di: María Fernanda Ordóñez-Rubiano, et al.
Pubblicazione: (2026)

Efficacy and Safety of Dupilumab in Children Aged 6 months–11 years Old With Atopic Dermatitis: A Systematic Review and Meta‐Analysis
di: Hua Wei, et al.
Pubblicazione: (2026)

Concordance Between Patient‐ and Physician‐Reported Improvement With Dupilumab in Atopic Dermatitis
di: Geena Conde, et al.
Pubblicazione: (2026)

Real‐World Experience of Dupilumab in Children and Adolescents With Atopic Dermatitis in Argentina
di: Margarita Larralde, et al.
Pubblicazione: (2025)

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis
di: Paul Sun Woo Kim, et al.
Pubblicazione: (2026)

Real‐World Effectiveness and Safety of Lebrikizumab in Moderate‐to‐Severe Atopic Dermatitis: A Multicenter Study From Spain
di: Jose Carlos Armario‐Hita, et al.
Pubblicazione: (2025)

Real‐World Efficacy and Safety of Dupilumab for Atopic Dermatitis in the Israeli Population
di: Raz Tshuva, et al.
Pubblicazione: (2025)

Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis
di: Grace Eleanor Sessler Bruess, et al.
Pubblicazione: (2025)

Increased Risk of Cutaneous T‐Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis
di: Jenna Mandel, et al.
Pubblicazione: (2024)

Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis
di: Niccolò Gori, et al.
Pubblicazione: (2024)

Corrigendum to “Effectiveness and Safety of Abrocitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials”
Pubblicazione: (2025)

A Real‐World Retrospective Cohort Study on the Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged 6 Months to 16 Years
di: Laura Wheller, et al.
Pubblicazione: (2025)

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long‐Term Treatment With Dupilumab: A Single‐Center Retrospective Study
di: Ayu Watanabe, et al.
Pubblicazione: (2025)

Extension of Secukinumab and Ixekizumab Dose for Moderate‐To‐Severe Psoriasis in Low Disease Activity Intervals
di: Caiyu Wang, et al.
Pubblicazione: (2025)

Effectiveness and Tolerability of an Emollient “Plus” Compared to Urea 10% in Patients With Mild‐to‐Moderate Atopic Dermatitis
di: Cita Rosita Sigit Prakoeswa, et al.
Pubblicazione: (2025)

Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience
di: Amanda Xin Yi Yap, et al.
Pubblicazione: (2024)

Effect of Dupilumab Therapy on Patch Test Results for Atopic Contact Dermatitis: A Systematic Review
di: Dennis Chu, et al.
Pubblicazione: (2025)

Atopic Dermatitis in Indonesian Children: Association of Toilet Seat Dermatitis With Moderate–Severe Manifestation and Low Prevalence of Loss‐of‐Function Filaggrin Gene Variants
di: Raden Mohamad Rendy Ariezal Effendi, et al.
Pubblicazione: (2025)

Atopic Dermatitis
Pubblicazione: (2026)

Lebrikizumab After Multiple Prior Advanced Therapies in Moderate‐To‐Severe Atopic Dermatitis: A Real‐World Case Series
di: Giovanni Paolino, et al.
Pubblicazione: (2026)

The Usefulness of Atopic Dermatitis Control Tool in Upadacitinib Treatment for Patients with Atopic Dermatitis
di: Teppei Hagino, et al.
Pubblicazione: (2024)

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study
di: Mizuki Shiba, et al.
Pubblicazione: (2026)

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real‐Life Study
di: Edoardo Mortato, et al.
Pubblicazione: (2025)

Predictive Factors of Super‐Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real‐World Monocentric Study
di: Edoardo Mortato, et al.
Pubblicazione: (2026)

Diagnostic Implications of Dupilumab‐Refractory Atopic Dermatitis: Risk of Underlying Cutaneous T‐Cell Lymphoma and the Role of Skin Biopsy
di: Sahithi Talasila, et al.
Pubblicazione: (2026)

Patient‐Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate‐To‐Severe Disease: Results of a Real‐World, Cross‐Sectional Survey
di: Lawrence F. Eichenfield, et al.
Pubblicazione: (2025)

Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis
di: Hideyuki Nakajima, et al.
Pubblicazione: (2024)

Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study
di: Matthew H. Lanehart, et al.
Pubblicazione: (2025)

The Role of Macrophages in Atopic Dermatitis
di: Xue Chen, et al.
Pubblicazione: (2026)

Labial Melanotic Macules in Two Pediatric Patients of Chinese Descent With Atopic Dermatitis
di: Apostolos Katsiaunis, et al.
Pubblicazione: (2025)

Efficacy and Safety of GR1802 in Patients With Moderate‐to‐Severe Atopic Dermatitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial
di: Shangshang Wang, et al.
Pubblicazione: (2025)

Comparisons of Efficacy and Safety of Different Doses of Doxycycline for the Treatment of Moderate‐to‐Severe Acne Vulgaris: A Systematic Review and Network Meta‐Analysis
di: Shuxian Shang, et al.
Pubblicazione: (2025)